A new gut-based procedure might help people avoid regaining weight after stopping popular medications like Ozempic or semaglutide. This minimally invasive outpatient procedure could reset metabolism in the small intestine. It helped patients keep much more of their weight loss.
About 70% of people who stop these drugs regain a lot of the weight they lost. This often happens within 18 months. Nearly one in five adults with obesity has used a GLP-1 drug, showing how common this challenge is.
Researchers presented the first blinded, randomized, sham-controlled evidence for this procedure. It's called duodenal mucosal resurfacing. It may offer a safe and lasting way to keep weight off without needing ongoing medication. The findings suggest it could help patients hold onto the benefits from drugs like Ozempic.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxShelby Sullivan, MD, a lead author, noted that many people stop GLP-1 medications due to cost, side effects, or not wanting long-term drug use. She said that when people stop, weight regain is common, and metabolic benefits are lost. Finding a treatment to prevent this is a huge unmet need. These findings suggest this procedure could provide lasting weight-loss maintenance.
How the "Gut Reset" Procedure Works
Duodenal mucosal resurfacing is an experimental treatment. It uses an endoscope and controlled heat to remove damaged tissue from the duodenum. This is the first part of the small intestine, right below the stomach. This process burns away unhealthy tissue, encouraging new, healthier tissue to grow.
The ongoing REMAIN-1 trial is testing if renewing the intestinal lining can create a lasting metabolic reset. This could help the body maintain weight loss after stopping medications like semaglutide or tirzepatide.
Trial Results Show Less Weight Regain
Early results from a group of participants with six months of follow-up data are promising. Forty-five people were in this group. Twenty-nine received the resurfacing treatment, and 16 had a sham procedure. All participants had lost at least 15% of their body weight using tirzepatide before stopping the drug.
On average, patients lost about 40 pounds while on GLP-1 therapy. Six months after stopping the medication, the control group regained much more weight. Those who had the sham procedure regained about 40% more weight than those who had the actual treatment.
Patients who had more extensive resurfacing regained only about seven pounds. They kept over 80% of their weight loss. The control group, however, regained roughly twice as much. The difference between the two groups grew from one to six months after the procedure. This suggests the benefits might last and even get stronger over time.
Dr. Sullivan found it encouraging that the benefit seemed to increase over time. She also noted it acted like a drug in terms of dose response. This gives researchers confidence they are targeting the right biology.
Safety and Recovery
No serious problems were reported from the device or the procedure. Recovery is quite fast. Most patients return to normal activities in about a day.
Dr. Sullivan explained that recovery time is minimal, apart from waking up from general anesthesia. She said participants couldn't tell if they had the sham or real procedure because there are few symptoms afterward.
Why the Gut Is Key to Weight Regulation
This treatment targets the small intestine. This is where many hormones affected by GLP-1 drugs are made. Over time, diets high in fat and sugar can change the lining of the duodenum. This alters how the body processes food and regulates hormones. These changes can lead to insulin resistance and metabolic disease.
By restoring a healthier mucosal layer, the procedure aims to reset how the body reacts to food. This could help stabilize metabolism at a lower body weight after stopping medications like Ozempic.
What Comes Next
Duodenal mucosal resurfacing is still being studied. The larger REMAIN-1 study has over 300 participants and is fully enrolled. Researchers expect six-month data from the main group in late 2026. A marketing submission is planned for later that year.
Dr. Sullivan will present these findings at Digestive Disease Week 2026. The study is titled "Duodenal mucosal resurfacing prevents weight regain after tirzepatide withdrawal: REMAIN-1 multicenter, randomized, double-blind, sham-controlled clinical trial -- midpoint cohort results."
Deep Dive & References
Duodenal mucosal resurfacing prevents weight regain after tirzepatide withdrawal: REMAIN-1 multicenter, randomized, double-blind, sham-controlled clinical trial -- midpoint cohort results - Digestive Disease Week, 2026
